1-20 of 78
Shaomeng Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3881: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression

Free
Haibin Zhou, Dimin Wu, Longchuan Bai, Ranjan K. Acharyya, Hoda Metwally, Donna McEachern, Bo Wen, Duxin Sun, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3881.
https://doi.org/10.1158/1538-7445.AM2024-3881
Published: 22 March 2024
View articletitled, Abstract 3881: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression
Journal Articles

Abstract 1969: Off-target autophagy inhibition by SHP2 allosteric inhibitors and therapeutic implications for aberrant RAS-driven cancers

Free
Yiming Miao, Yunpeng Bai, Jinmin Miao, Allison A. Murray, Jianping Lin, Jiajun Dong, Zihan Qu, Ruo-Yu Zhang, Quyen Nguyen, Shaomeng Wang, Zhong-Yin Zhang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1969.
https://doi.org/10.1158/1538-7445.AM2024-1969
Published: 22 March 2024
View articletitled, Abstract 1969: Off-target autophagy inhibition by SHP2 allosteric inhibitors and therapeutic implications for aberrant RAS-driven cancers
Journal Articles

Abstract 2656: The selective IKZF2 molecular glue degrader, PVTX-405, counters Treg immune suppression,shows significant tumor growth delay as single agent and synergistic response with immune checkpoint therapies (ICTs)

Free
Harshil D. Dhruv, Donna McEachern, Longchuan Bai, Xuqing Zhang, Zhixiang Chen, Rakesh Nagilla, Elham Behshad, Bomie Han, Peter Orth, Rohan Rej, Paul Kirchhoff, Niu Shin, Larry Jolivette, Corey Strickland, Zhihua Sui, Scott Priestley, Shaomeng Wang, Helai Mohammad
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2656.
https://doi.org/10.1158/1538-7445.AM2024-2656
Published: 22 March 2024
View articletitled, Abstract 2656: The selective IKZF2 molecular glue degrader, PVTX-405, counters Treg immune suppression,shows significant tumor growth delay as single agent and synergistic response with immune checkpoint therapies (ICTs)
Journal Articles

Abstract 4515: Orally bioavailable PROTAC based MDM2 degrader

Free
Angelo Aguilar, Jiuling Yang, Yangbing Li, Donna McEachern, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4515.
https://doi.org/10.1158/1538-7445.AM2024-4515
Published: 22 March 2024
View articletitled, Abstract 4515: Orally bioavailable PROTAC based MDM2 degrader
Journal Articles

Abstract 6057: Evaluation of a highly potent and selective STAT3 degrader as a new class of immunotherapy

Free
Longchuan Bai, Haibin Zhou, Jiajia Zhou, Dimin Wu, Ranjan Kumar Acharyya, Hoda Metwally, Donna McEachern, Bo Wen, Duxin Sun, Weiping Zou, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6057.
https://doi.org/10.1158/1538-7445.AM2024-6057
Published: 22 March 2024
View articletitled, Abstract 6057: Evaluation of a highly potent and selective STAT3 degrader as a new class of immunotherapy
Journal Articles

Abstract 4510: Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα)

Free
Rohan K. Rej, Zhixiang Chen, Ranjan K. Acharyya, Dimin Wu, Biao Hu, Guozhang Xu, Rakesh Nagilla, Hoda Metwally, Yu Wang, Bo Wen, Duxin Sun, Longchuan Bai, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4510.
https://doi.org/10.1158/1538-7445.AM2024-4510
Published: 22 March 2024
View articletitled, Abstract 4510: Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα)
Journal Articles

Abstract 6048: Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader

Free
Jie luo, Abhijit Prolia, Yuanyuan Qiao, Jean Tian, Rahul Mannan, Somnath Mahapatra, Zhixiang Chen, Rithvik Seri, Shaomeng Wang, Arul Chinnaiyan
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6048.
https://doi.org/10.1158/1538-7445.AM2024-6048
Published: 22 March 2024
View articletitled, Abstract 6048: Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader
Journal Articles

Abstract 4506: Discovery of potent, highly selective and orally efficacious SMARCA2 degraders

Free
Lingying Leng, Lin Yang, Wenbin Tu, Rohan Rej, Srinivasa Rao Allu, Liyue Huang, Wei Jiang, Yu Wang, Jeanne Stuckey, Farzad R Sarkari, Meilin Wang, Lu Wang, Bo Wen, Duxin Sun, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4506.
https://doi.org/10.1158/1538-7445.AM2024-4506
Published: 22 March 2024
View articletitled, Abstract 4506: Discovery of potent, highly selective and orally efficacious SMARCA2 degraders
Journal Articles

Abstract 4519: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving complete tumor regression

Free
Haibin Zhou, Dimin Wu, Longchuan Bai, Ranjan K. Acharyya, Hoda Metwally, Donna McEachern, Bo Wen, Duxin Sun, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4519.
https://doi.org/10.1158/1538-7445.AM2024-4519
Published: 22 March 2024
View articletitled, Abstract 4519: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving complete tumor regression
Journal Articles

Abstract 3879: Development of potent, highly selective and efficacious SMARCA2 degraders

Free
Lin Yang, Wenbin Tu, Liyue Huang, Lingying Leng, Wei Jiang, Meilin Wang, Bo Wen, Duxin Sun, Jeanne Stuckey, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3879.
https://doi.org/10.1158/1538-7445.AM2024-3879
Published: 22 March 2024
View articletitled, Abstract 3879: Development of potent, highly selective and efficacious SMARCA2 degraders
Journal Articles

Abstract 4509: Discovery of potent and highly efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression

Free
Ranjan K. Acharyya, Longchuan Bai, Haibin Zhao, Dimin Wu, Metwally Hoda, McEachern Donna, Wen Bo, Duxin Sun, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4509.
https://doi.org/10.1158/1538-7445.AM2024-4509
Published: 22 March 2024
View articletitled, Abstract 4509: Discovery of potent and highly efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression
Journal Articles

Abstract 4504: Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer

Free
Zhixiang Chen, Mi Wang, Dimin Wu, Lijie Zhao, Tianfeng Xu, Hoda Metwally, Yu Wang, Donna McEachern, Wei Jiang, Longchuan Bai, Jie Luo, Meilin Wang, Ruiting Li, John Takyi-Williams, Lu Wang, Qiuxia Li, Bo Wen, Duxin Sun, Arul M. Chinnaiyan, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4504.
https://doi.org/10.1158/1538-7445.AM2024-4504
Published: 22 March 2024
View articletitled, Abstract 4504: Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer
Journal Articles

Abstract 2664: Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors

Free
Shaoulai Gu, Qiang Li, Chao Li, Qixin Wang, Douglas D. Fang, Shaomeng Wang, Dajun Yang, Yifan Zhai
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2664.
https://doi.org/10.1158/1538-7445.AM2022-2664
Published: 15 June 2022
View articletitled, Abstract 2664: Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors
Journal Articles

Abstract 428: Therapeutic potential of the novel SHP2 degrader, SHP2-D26, alone or in combination, in the treatment of lung cancer

Free
Yunful Deng, Guangzhi Ma, Karin A. Vallega, Dongsheng Wang, Mingliang Wang, Changwei Wang, Shaomeng Wang, Suresh S. Ramalingam, Shi-Yong Sun
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 428.
https://doi.org/10.1158/1538-7445.AM2022-428
Published: 15 June 2022
View articletitled, Abstract 428: Therapeutic potential of the novel SHP2 degrader, SHP2-D26, alone or in combination, in the treatment of lung cancer
Journal Articles

Abstract 3939: Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918/EEDi-5273 for cancer therapy

Free
Saijie Zhu, Douglas D. Fang, Qiang Li, Dongmei Yang, Shoulai Gu, Shaomeng Wang, Dajun Yang, Yifan Zhai
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3939.
https://doi.org/10.1158/1538-7445.AM2022-3939
Published: 15 June 2022
View articletitled, Abstract 3939: Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918/EEDi-5273 for cancer therapy
Journal Articles

Abstract 1231: Identification of selective Brd4 degrader for cancer treatment

Free
Biao Hu, Jiantao Hu, fuming Xu, Liyue Huang, Mi Wang, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1231.
https://doi.org/10.1158/1538-7445.AM2021-1231
Published: 01 July 2021
View articletitled, Abstract 1231: Identification of selective Brd4 degrader for cancer treatment
Journal Articles

Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunities

Free
Liang Xu, Ye Chen, Yulun Huang, Edwin Sandanaraj, John S. Yu, Ruby Yu-Tong Lin, Pushkar Dakle, Xin-Yu Ke, Yuk Kien Chong, Lynnette Koh, Anand Mayakonda, Kassoum Nacro, Jeffrey Hill, Mo-Li Huang, Sigal Gery, See Wee Lim, Zhengyun Huang, Ying Xu, Jianxiang Chen, Longchuan Bai, Shaomeng Wang, Hiroaki Wakimoto, Tseng Tsai Yeo, Beng Ti Ang, Markus Müschen, Carol Tang, Tuan Zea Tan, Phillip H. Koeffler
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2123.
https://doi.org/10.1158/1538-7445.AM2021-2123
Published: 01 July 2021
View articletitled, Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunities
Journal Articles

Abstract 1036: Discovery of a highly potent, efficacious and orally active small-molecule inhibitor of embryonic ectoderm development (EED)

Free
Changwei Wang, Rohan Kalyan Rej, Jianfeng Lu, Mi Wang, Kaitlin P. Harvey, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey, Elyse Petrunak, Caroline Foster, Yunlong Zhou, Rubin Zhou, Guozhi Tang, Jianyong Chen, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1036.
https://doi.org/10.1158/1538-7445.AM2020-1036
Published: 15 August 2020
View articletitled, Abstract 1036: Discovery of a highly potent, efficacious and orally active small-molecule inhibitor of embryonic ectoderm development (EED)
Journal Articles

Abstract 1960: Targeted androgen receptor (AR) protein degradation for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Free
Xin Han, Lijie Zhao, Weiguo Xiang, Chong Qin, Bukeyan Miao, Tianfeng Xu, Jianfeng Lu, Mi Wang, Shaomeng Wang
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1960.
https://doi.org/10.1158/1538-7445.AM2020-1960
Published: 15 August 2020
View articletitled, Abstract 1960: Targeted androgen receptor (AR) protein degradation for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

Free
Steven Kregel, Chao Wang, Xin Han, Lanbo Xiao, Ester Fernandez-Salas, Pushpinder Bawa, Brooke L. McCollum, Kari Wilder-Romans, Ingrid J. Apel, Xuhong Cao, Corey Speers, Shaomeng Wang, Arul M. Chinnaiyan
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5679.
https://doi.org/10.1158/1538-7445.AM2020-5679
Published: 15 August 2020
View articletitled, Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment